March 3 (Reuters) - Traws Pharma TRAW.O:
TRAWS PHARMA: REPORTS POSITIVE RESULTS FROM ACCEPTED BIRD FLU MODEL FOR ANTI-VIRAL CANDIDATE, TIVOXAVIR MARBOXIL
TRAWS PHARMA: TOPLINE DATA FROM FERRET MODEL TESTING SHOW THAT TIVOXAVIR MARBOXIL HAS POTENTIAL TO INHIBIT DISEASE AFTER BIRD FLU INFECTION
TRAWS PHARMA: CONDUCTING SIMILAR CHALLENGE STUDY IN NON-HUMAN PRIMATES, WITH DATA EXPECTED IN Q1 2025
Source text: [ID:]
Further company coverage: TRAW.O
((Reuters.Briefs@thomsonreuters.com;))